All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Skyepharma plc, of London, said partner Mundipharma International Corp. Ltd., of Singapore, received confirmation that its marketing authorization application for a breath-actuated version of flutiform was accepted for review in Europe. Mundipharma is seeking approval for treating asthma in adults and adolescents where the use of a combination product (inhaled corticosteroid/long-acting beta2 agonist) is appropriate.